JSE-listed pharmaceutical manufacturer Adcock Ingram has reported a 6% year-on-year increase in revenue, from about R9.1-billion in 2023 to about R9.6-billion for the financial year ended June 30. Trading profit also increased by 4% year-on-year, from about R1.1-billion to about R1.2-billion. Gross profit increased by 1% year-on-year, from about R3.1-billion to about R3.2-billion, while operating profit declined by 6%, from about R1.1-billion to about R1-billion.
